Ethical Implications of Artificial Intelligence in Vaccine Equity: Protocol for Exploring Vaccine Distribution Planning and Scheduling in Pandemics in Low- and Middle-Income Countries.

BACKGROUND

The COVID-19 pandemic highlighted significant disparities in vaccine distribution, particularly in low- and middle-income countries (LMICs). Artificial intelligence (AI) has emerged as a potential tool to optimize vaccine distribution planning and scheduling. However, its ethical implications, including equity, transparency, bias, and accessibility, remain underexplored. Ensuring ethical AI implementation in vaccine distribution is crucial to addressing health equity challenges worldwide.

OBJECTIVE

This study aims to assess the ethical implications of AI-assisted vaccine distribution planning and scheduling in LMICs during pandemics. It seeks to evaluate AI's role in ensuring equitable vaccine access, analyze ethical concerns associated with its deployment, and propose an ethical framework to guide AI-based vaccine distribution strategies.

METHODS

Our multiphase qualitative research approach will combine a systematic scoping review, a witness seminar with key stakeholders (health care professionals, AI developers, policymakers, and bioethicists), and a meta-synthesis of findings. The scoping review will follow PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews) guidelines, focusing on studies from 2019 to 2023. The witness seminar will provide firsthand insights into AI's ethical impact on vaccine equity. Thematic content analysis and qualitative coding will be used for data interpretation, with findings integrated into a policy-driven ethical framework.

RESULTS

This study received institutional ethical approval in October 2023. Recruitment commenced in mid-August 2024 through email requests to prospective participants, and recruitment for the witness seminar (focus group discussion) is still ongoing, with 7 expert participants confirmed. Data collection is projected to conclude by August 2025. Preliminary literature analysis from the scoping review is ongoing, and qualitative data analysis from the witness seminar is scheduled for September 2025. The final results and proposed ethical framework are expected to be published in early 2026.

CONCLUSIONS

By examining the ethical implications of AI in vaccine distribution, this research will provide actionable recommendations for policymakers, health care organizations, and AI developers. The findings will contribute to the discourse on responsible AI deployment in health care worldwide, ensuring transparency, fairness, and inclusivity in pandemic response strategies.

INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/76634.